Lipocine has completed the development of a prototype formulation of a new non-sedating, non-narcotic anti-tussive. A number of clinical formulations have been selected from early studies. LPCN 1035 is suitable for line extension combination products.
LPCN 1035 is also a longer acting version of a leading respiratory product.
Lipocine Inc. has multiple issued patents providing protection for the LPCN 1035 product.
Lipocine seeks any partners with strong marketing, manufacturing and late stage clinical capabilities to develop this product further.